Hong Kong Industry Calls For Formation Of Local FDA In Biotech Drive
Executive Summary
Local industry insiders argue that a full-fledged drug regulator would boost the chances of making Hong Kong an international innovation and biotechnology center, by elevating the city's role from a transit corridor to a platform for biomedicine review and approval.
You may also be interested in...
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Hengrui, BeyondSpring In Arbitration Face-Off After Cancer Deal Setbacks
A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.